Sharon Benzeno - Mar 4, 2025 Form 4 Insider Report for Adaptive Biotechnologies Corp (ADPT)

Role: Chief Commercial Ofc Imm Med
Signature: /s/ Sharon Benzeno by Kyle Piskel, Attorney-in-Fact
Stock symbol: ADPT
Transactions as of: Mar 4, 2025
Transactions value $: -$311,792
Form type: 4
Date filed: 3/6/2025, 07:21 PM
Previous filing: Mar 6, 2024
Next filing: Nov 24, 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ADPT	Common Stock	Award	$0	+110K	+33.59%	$0.00	437K	Mar 4, 2025	Direct
transaction	ADPT	Common Stock	Sale	-$290K	-41.6K	-9.51%	$6.98	396K	Mar 5, 2025	Direct	F1
transaction	ADPT	Common Stock	Sale	-$21.4K	-3.07K	-0.77%	$6.99	393K	Mar 5, 2025	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ADPT	Stock Option (right to buy)	Award	$0	+165K		$0.00	165K	Mar 4, 2025	Common Stock	165K	$8.12	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
F2	The options vest with respect to 1/4 of such shares on March 4, 2026, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

Content

This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

The options vest with respect to 1/4 of such shares on March 4, 2026, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.